BioCentury | Oct 20, 2017
Company News

VIB grants Oncurious rights to five preclinical oncology assets

In September, the Flanders Institute for Biotechnology (VIB) (Ghent, Belgium) granted Oncurious N.V. (Leuven, Belgium) exclusive rights to a portfolio of five undisclosed immuno-oncology assets in exchange for an additional stake in Oncurious. The institute...
BioCentury | May 9, 2016
Clinical News

TB-403: Phase I/IIa started

Oncurious and BioInvent began an open-label, U.S. Phase I/IIa of IV TB-403 in >=27 patients ages 6 months to 18 years old. The dose-escalation Phase I portion will test 20-175 mg/kg TB-403. The Phase IIa...
BioCentury | May 25, 2015
Company News

ThromboGenics, Flanders Institute for Biotechnology (VIB), Oncurious deal

ThromboGenics and VIB launched Oncurious, a new company with worldwide, co-development rights to TB-403 for oncology. ThromboGenics will hold more than 90% of the newco, and VIB will own the remainder. Oncurious and co-development partner...
Items per page:
1 - 3 of 3
BioCentury | Oct 20, 2017
Company News

VIB grants Oncurious rights to five preclinical oncology assets

In September, the Flanders Institute for Biotechnology (VIB) (Ghent, Belgium) granted Oncurious N.V. (Leuven, Belgium) exclusive rights to a portfolio of five undisclosed immuno-oncology assets in exchange for an additional stake in Oncurious. The institute...
BioCentury | May 9, 2016
Clinical News

TB-403: Phase I/IIa started

Oncurious and BioInvent began an open-label, U.S. Phase I/IIa of IV TB-403 in >=27 patients ages 6 months to 18 years old. The dose-escalation Phase I portion will test 20-175 mg/kg TB-403. The Phase IIa...
BioCentury | May 25, 2015
Company News

ThromboGenics, Flanders Institute for Biotechnology (VIB), Oncurious deal

ThromboGenics and VIB launched Oncurious, a new company with worldwide, co-development rights to TB-403 for oncology. ThromboGenics will hold more than 90% of the newco, and VIB will own the remainder. Oncurious and co-development partner...
Items per page:
1 - 3 of 3